Human immunodeficiency virus type 1 proteinase resistance to symmetric cyclic urea inhibitor analogs

Resistant virus was isolated from virus propagated in cell culture in the presence of the human immunodeficiency virus type 1 (HIV-1) proteinase inhibitor DMP 323, Ro 31-8959, or A-75925. The proteinase gene of resistant virus was sequenced, and key mutations (G48V, V82A, I84V, L90M, and G48V/L90M) were introduced into clones used for the expression, purification, and further characterization of the enzyme. The mutant enzymes were all less active than the wild-type enzyme, as judged by k(cat) and k(cat)/Km values. L90M had a lower Km than the wild type, whereas the G48V/L90M double mutant had an increased Km compared with that of the wild type, contributing to a 10-fold reduction in the k(cat)/Km. Vitality values were used to show that the enzyme of the I84V mutant is the enzyme most resistant to the two cyclic urea inhibitors DMP 323 and AHA 008. Virus with the same mutation is also resistant, although the double mutation L10F/I84V confers even greater resistance. All of these mutants are more resistant to DMP 323 than to AHA 008. The resistance of the I84V mutant may be attributed to a loss of van der Waals interactions with the inhibitor, since the larger amino acid side chain involved in the interaction is replaced by a smaller side chain. This is supported by the lower level of resistance to AHA 008 that was observed. The phenyl groups of AHA 008 should protrude deeper into the S1 and S1' subsites than those of the smaller compound DMP 323, reducing the loss of interaction energy. These results reveal that small structural modifications of inhibitors that do not affect the inhibitory effect on wild-type virus can influence the inhibition of resistant strains. This is of importance for optimizing drugs with respect to their potency and resistance.

[1]  J. Condra,et al.  In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors , 1995, Nature.

[2]  S Foundling,et al.  Effect of point mutations on the kinetics and the inhibition of human immunodeficiency virus type 1 protease: relationship to drug resistance. , 1995, Biochemistry.

[3]  J. Eberle,et al.  Inhibition of HIV replication in cell culture by the specific aspartic protease inhibitor pepstatin A , 1989, FEBS letters.

[4]  E. Furfine,et al.  Analysis of resistance to human immunodeficiency virus type 1 protease inhibitors by using matched bacterial expression and proviral infection vectors , 1995, Journal of virology.

[5]  N. Roberts.  Drug-resistance patterns of saquinavir and other HIV proteinase inhibitors. , 1995, AIDS.

[6]  J. Morrison,et al.  The determination of kinetic constants governing the slow,tight-binding inhibition of enzyme-catalysed reactions , 1986 .

[7]  PatrickY.-S. Lam,et al.  Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors. , 1994, Science.

[8]  P. Volberding,et al.  HIV-1 protease inhibitors , 1992 .

[9]  L. Vrang,et al.  The use of 5′-Phosphate Derivatives of Nucleoside Analogues as Inhibitors of HIV-1 Replication , 1995 .

[10]  L J Davis,et al.  Active human immunodeficiency virus protease is required for viral infectivity. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[11]  D. Lamarre,et al.  Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors , 1996, Journal of virology.

[12]  M. Boyd,et al.  New soluble-formazan assay for HIV-1 cytopathic effects: application to high-flux screening of synthetic and natural products for AIDS-antiviral activity. , 1989, Journal of the National Cancer Institute.

[13]  R. Levine,et al.  Copper inhibits the protease from human immunodeficiency virus 1 by both cysteine-dependent and cysteine-independent mechanisms. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[14]  William G. Bardsley,et al.  Optimal design for model discrimination using the F-test with non-linear biochemical models. Criteria for choosing the number and spacing of experimental points , 1989 .

[15]  J. Coffin,et al.  HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy , 1995, Science.

[16]  J S Mills,et al.  Antiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase. , 1991, Antiviral research.

[17]  Chong-Hwan Chang,et al.  The molecular basis of HIV-1 protease drug resistance , 1996 .

[18]  S. Gulnik,et al.  Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. , 1995, Biochemistry.

[19]  L. Bacheler,et al.  Multiple Mutations in the Human Immunodeficiency Virus Protease Gene Are Responsible for Decreased Susceptibility to Protease Inhibitors , 1995 .

[20]  E D Blair,et al.  Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors , 1995, Antimicrobial agents and chemotherapy.

[21]  Philip R. Johnson,et al.  Antibodies to the putative SIV infection‐enhancing domain diminish beneficial effects of an SIV gp160 vaccine in rhesus macaques , 1995, AIDS.

[22]  J L Meek,et al.  Improved cyclic urea inhibitors of the HIV-1 protease: synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450. , 1996, Chemistry & biology.

[23]  S. Vasavanonda,et al.  Structure-based, C2 symmetric inhibitors of HIV protease. , 1990, Journal of medicinal chemistry.

[24]  J. Åqvist,et al.  Cyclic HIV-1 protease inhibitors derived from mannitol: synthesis, inhibitory potencies, and computational predictions of binding affinities. , 1997, Journal of medicinal chemistry.